Literature DB >> 21738054

Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment.

Vin-Cent Wu1, Chin-Chi Kuo, Shuo-Meng Wang, Kao-Lang Liu, Kuo-How Huang, Yen-Hung Lin, Tzong-Shinn Chu, Hung-Wei Chang, Chien-Yu Lin, Chia-Ti Tsai, Lian-Yu Lin, Shih-Chieh Chueh, Tze-Wah Kao, Yung-Ming Chen, Wen-Chih Chiang, Tun-Jun Tsai, Yi-Luwn Ho, Shuei-Liong Lin, Wei-Jei Wang, Kwan-Dun Wu.   

Abstract

OBJECTIVES: To obtain information about the effect of prolonged aldosterone excess on kidney function.
METHODS: We determined kidney function changes defined by cystatin C-based estimations of glomerular filtration rate (CysC-GFR). Pretreatment proteinuria and intrarenal Doppler velocimetric indices in primary aldosteronism were examined and followed after adrenalectomy or spironolactone treatment.
RESULTS: This prospective, multicenter study included 130 primary aldosteronism patients (56 men; age, 49.9 ± 13.4 years: 100 with adenoma and 30 with idiopathic hyperaldosteronism) and 73 essential hypertension patients (36 men; age, 51.4 ± 14.8 years) as controls. Patients with primary aldosteronism had higher CysC-GFR (P < 0.05) and heavier proteinuria (0.042) than those with essential hypertension. With primary aldosteronism, a higher aldosterone-renin ratio (odds ratio, OR = 7.85, P = 0.008) was independently related to pretreatment CysC-GFR. The factors related to pretreatment proteinuria included CysC-GFR (OR, -0.006, P = 0.001), plasma aldosterone concentration (OR, 0.004, P = 0.002), and duration of hypertension (OR, 0.016, P = 0.032). Duration of hypertension was also independently correlated with the pretreatment resistive index among primary aldosteronism patients (OR, 0.004, P = 0.035). CysC-GFR (all, P < 0.05), proteinuria (P < 0.001), and resistive index (P < 0.001) decreased 1 year after adrenalectomy but not with spironolactone treatment.
CONCLUSION: Our data suggest that prolonged hyperaldosteronism will cause relative kidney hyperfiltration and reversible intrarenal vascular structural changes, which disguise the consequent renal injury, including declining GFR and proteinuria. Adrenalectomy and spironolactone treatment exert different clinical impacts toward kidney damage even with a similar blood pressure-lowering effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21738054     DOI: 10.1097/HJH.0b013e3283495cbb

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  20 in total

Review 1.  MANAGEMENT OF ENDOCRINE DISEASE: The role of surgical adrenalectomy in primary aldosteronism.

Authors:  Gregory L Hundemer; Anand Vaidya
Journal:  Eur J Endocrinol       Date:  2020-12       Impact factor: 6.664

2.  Worsening of lipid metabolism after successful treatment of primary aldosteronism.

Authors:  Christian Adolf; Evelyn Asbach; Anna Stephanie Dietz; Katharina Lang; Stefanie Hahner; Marcus Quinkler; Lars Christian Rump; Martin Bidlingmaier; Marcus Treitl; Roland Ladurner; Felix Beuschlein; Martin Reincke
Journal:  Endocrine       Date:  2016-05-14       Impact factor: 3.633

3.  Aldosterone-producing adenoma associated with non-suppressed renin: a case series.

Authors:  Pieter Martijn Jansen; Michael Stowasser
Journal:  J Hum Hypertens       Date:  2021-03-30       Impact factor: 3.012

4.  A Novel Somatic Mutation of CACNA1H p.V1937M in Unilateral Primary Hyperaldosteronism.

Authors:  Chi-Shin Tseng; Kang-Yung Peng; Shuo-Meng Wang; Yao-Chou Tsai; Kuo-How Huang; Wei-Chou Lin; Ya-Hui Hu; Vin-Cent Wu; Jeff S Chueh
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

5.  A Bibliometric Analysis of Primary Aldosteronism Research From 2000 to 2020.

Authors:  Chengyuan Wang; Hongwei Jing; Zuyu Sun; Jiaxi Yao; Xinyu Zhang; Tao Liu; Ying Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-27       Impact factor: 5.555

6.  The Association between Glomerular Hyperfiltration and Left Ventricular Structure and Function in Patients with Primary Aldosteronism.

Authors:  Min-Tsun Liao; Xue-Ming Wu; Chin-Chen Chang; Che-Wei Liao; Ying-Hsien Chen; Ching-Chu Lu; Yen-Ting Lin; Yi-Yao Chang; Chi-Sheng Hung; Lung-Chun Lin; Chao-Lun Lai; Lian-Yu Lin; Vin-Cent Wu; Yi-Lwun Ho; Kwan-Dun Wu; Yen-Hung Lin
Journal:  Int J Med Sci       Date:  2015-05-03       Impact factor: 3.738

7.  Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population.

Authors:  Vin-Cent Wu; Kuo-How Huang; Kang-Yung Peng; Yao-Chou Tsai; Che-Hsiung Wu; Shuo-Meng Wang; Shao-Yu Yang; Lian-Yu Lin; Chin-Chen Chang; Yen-Hung Lin; Shuei-Liong Lin; Tzong-Shinn Chu; Kwan-Dun Wu
Journal:  Sci Rep       Date:  2015-06-12       Impact factor: 4.379

8.  Effect of Treatment on Body Fluid in Patients with Unilateral Aldosterone Producing Adenoma: Adrenalectomy versus Spironolactone.

Authors:  Che-Hsiung Wu; Ya-Wen Yang; Szu-Chun Hung; Yao-Chou Tsai; Ya-Hui Hu; Yen-Hung Lin; Tzong-Shinn Chu; Kwan-Dun Wu; Vin-Cent Wu
Journal:  Sci Rep       Date:  2015-10-19       Impact factor: 4.379

9.  Long term outcome of Aldosteronism after target treatments.

Authors:  Vin-Cent Wu; Shuo-Meng Wang; Chia-Hui Chang; Ya-Hui Hu; Lian-Yu Lin; Yen-Hung Lin; Shih-Chieh Jeff Chueh; Likwang Chen; Kwan-Dun Wu
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

10.  Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients.

Authors:  Che-Wei Liao; Lian-Yu Lin; Chi-Sheng Hung; Yen-Tin Lin; Yi-Yao Chang; Shuo-Meng Wang; Vin-Cent Wu; Kwan-Dun Wu; Yi-Lwun Ho; Fumitoshi Satoh; Yen-Hung Lin
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.